Essential medicines for cancer: WHO recommendations and national priorities

被引:83
|
作者
Robertson, Jane [1 ]
Barr, Ronald [2 ]
Shulman, Lawrence N. [3 ]
Forte, Gilles B.
Magrini, Nicola [4 ]
机构
[1] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia
[2] McMaster Univ, Dept Pediat Pathol & Med, Hamilton, ON, Canada
[3] Univ Penn, Ctr Global Canc Med, Philadelphia, PA 19104 USA
[4] World Hlth Org, Dept Essential Med & Hlth Prod, 20 Ave Appla, CH-1211 Geneva 27, Switzerland
关键词
CLINICAL ONCOLOGY; AMERICAN SOCIETY; MIDDLE; SELECTION; CHILDREN; BENEFIT; PRICE; COST; CARE;
D O I
10.2471/BLT.15.163998
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective To examine, for essential anti-cancer medicines, the alignment of national lists of essential medicines and national reimbursable medicines lists with the World Health Organization's (WHO's) Model Lists. Methods National medicine lists for 135 countries with per-capita gross national incomes below 25 000 United States dollars in 2015 were compared with WHO's 2013 and 2015 Model Lists of Essential Medicines. Correlations between numbers of anti-cancer medicines included in national lists and gross national income (GNI), government health expenditure and number of physicians per 1000 population were evaluated. Findings Of the 25 anti-cancer medicines on the 2013 Model List and the 16 added via the 2015 revision of the Model List, 0-25 (median: 17) and 0-15 (median: 3) appeared in national lists, respectively. There was considerable variability in these numbers within and between World Bank income groups. Of the 16 new medicines included in the 2015 Model List, for example, 0-10 (median: 1) and 2-15 (median: 10) were included in the national lists of low-income and high-income countries, respectively. The numbers of these new medicines included in national lists were significantly correlated (P <= 0.0001) with per-capita GNI (r=0.45), per-capita annual government health expenditure (r= 0.33) and number of physicians per 1000 population (r=0.48). Twenty-one countries (16%) included the targeted anti-cancer medicines imatinib, rituximab and trastuzumab in their national lists. Conclusion Substantial numbers of anti-cancer medicines are included in national lists of low- and middle-income countries but the availability, affordability, accessibility and administration feasibility, of these medicines, at country-level, need assessment.
引用
收藏
页码:735 / 742
页数:8
相关论文
共 50 条
  • [31] Essential medicines for children with cancer
    Barr, Ronald D.
    PEDIATRIC BLOOD & CANCER, 2013, 60 (05) : 888 - 888
  • [32] Comparative Analysis of ADR on China's National Essential Medicines List (2015 Edition) and WHO Model List of Essential Medicines (19th Edition)
    Zheng, Fangfang
    Chen, Hongdou
    Chen, Yanfang
    Ye, Lu
    Wu, Huanhuan
    BIOMED RESEARCH INTERNATIONAL, 2018, 2018
  • [33] The Selection and Use of Essential Medicines Report of the WHO Expert Committee, 2017 (including the 20th WHO Model List of Essential Medicines and the 6th WHO Model List of Essential Medicines for Children)
    SELECTION AND USE OF ESSENTIAL MEDICINES: REPORT OF THE WHO EXPERT COMMITTEE, 2017 (INCLUDING THE 20TH WHO MODEL LIST OF ESSENTIAL MEDICINES AND THE 6TH WHO MODEL LIST OF ESSENTIAL MEDICINES FOR CHILDREN), 2017, 1006 : I - +
  • [34] Integrating obesity medicines in the national list of essential medicines: a policy concern
    Sindhwani, Ritika
    Bora, Kundan Singh
    Hazra, Subhajit
    CURRENT SCIENCE, 2024, 127 (06): : 660 - 661
  • [35] A comparison of national essential medicines lists in the Americas
    Steiner, Liane
    Maraj, Darshanand
    Woods, Hannah
    Jarvis, Jordan
    Yaphe, Hannah
    Adekoya, Itunu
    Bali, Anjli
    Persaud, Nav
    REVISTA PANAMERICANA DE SALUD PUBLICA-PAN AMERICAN JOURNAL OF PUBLIC HEALTH, 2020, 44
  • [37] Priorities on medicines
    Alder, M
    VETERINARY RECORD, 2002, 151 (12) : 337 - 337
  • [38] Medicines not recommended for inclusion in the who essential medicines list: a retrospective observational study
    Costa, Enrico
    Del Grosso, Vittorio
    Cappello, Bernadette
    Genazzani, Armando A.
    Huttner, Benedikt
    Leufkens, Hubert G. M.
    Magrini, Nicola
    Nonino, Francesco
    Wirtz, Veronika J.
    van den Ham, Hendrika A.
    Moja, Lorenzo
    FRONTIERS IN MEDICINE, 2025, 12
  • [39] Essential Medicines at the National Level: The Global Asthma Network's Essential Asthma Medicines Survey 2014
    Bissell, Karen
    Ellwood, Philippa
    Ellwood, Eamon
    Chiang, Chen-Yuan
    Marks, Guy B.
    El Sony, Asma
    Asher, Innes
    Billo, Nils
    Perrin, Christophe
    Asher, I
    Billo, N. E.
    Bissell, K.
    Chiang, C-Y
    El Sony, A.
    Ellwood, P.
    Garcia-Marcos, L.
    Mallol, J.
    Marks, G. B.
    Pearce, N.
    Strachan, D.
    Priftanji, A.
    Boukari, R.
    Taright, S.
    Gomez, M.
    Baghdasaryan, A.
    Burgess, S.
    Marks, G. B.
    Mattes, J.
    Tai, A.
    Riedler, J.
    Shpakou, A.
    Weyler, J.
    Lawin, H.
    de Abruzzese, Aguirre J.
    Domuz, S.
    Brandao, H., V
    Camargos, P. A. M.
    Fischer, G. B.
    Menezes, A. M.
    Porto Neto, A. C.
    Rosario, N.
    Sole, D.
    Mustakov, T. B.
    Birba, E.
    Ngahane, Mbatchou B. H.
    Tse, S. M.
    Standring, P.
    Aguirre, V
    Calvo Gil, M. A.
    Chen, Y-Z
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2019, 16 (04)
  • [40] WHO Essential Medicines List for ChildrenImpact on Patient Outcomes?
    Andy Gray
    Pediatric Drugs, 2011, 13 : 209 - 211